Showing results (2271-2280 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|August 16, 2023
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United KingdomJason Gordon, Maria Gheorghe, Simon Goldenberg, et al.
Pharmacoeconomics|September 22, 2023
A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes MellitusMarina Antoniou, Céu Mateus, Bruce Hollingsworth, et al.
Pharmacoeconomics|July 11, 2023
Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact ModelKathrin Pahmeier, Christian Speckemeier, Silke Neusser, et al.
Pharmacoeconomics|June 21, 2023
Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: An Updated Methodological ReviewJudith Dams, Johann-Jacob Zapp, Hans-Helmut König
Pharmacoeconomics|February 5, 2019
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in SwedenSantiago Zuluaga-Sanchez, Megan Teynor, Christopher Knight, et al.
Pharmacoeconomics|September 8, 2020
Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer?Luke B Connelly, Stephen Birch
Pharmacoeconomics|September 14, 2020
Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk ProfilesChing-Yu Wang, Phuong N Pham, Thuy N Thai, et al.
Pharmacoeconomics|October 7, 2020
The Relative Importance of Education and Criminal Justice Costs and Benefits in Economic Evaluations: A Best-Worst Scaling ExperimentIrina Pokhilenko, Luca M M Janssen, Mickael Hiligsmann, et al.
Pharmacoeconomics|October 7, 2020
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for OsteoporosisNannan Li, Dennis Cornelissen, Stuart Silverman, et al.
Pharmacoeconomics|April 3, 2020
Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in SwedenJulia Widén, Magnus Ivarsson, Lovisa Schalin, et al.
Pageof 336